Patents by Inventor Paul J. Brackemeyer
Paul J. Brackemeyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190202812Abstract: The present invention features crystalline polymorphs of dimethyl (2S,2?S)-1,1,-((2S,2?S)-2,2,-(4,4,-((2S,5S)-1-(4-tert-butylphenyl) pyrrolidine-2,5-diyl) bis (4,1-phenylene)) bis (azanediyl) bis (oxomethylene) bis (pyrrolidine-2,1-diyl)) bis (3-methyl-1-oxobutane-2,1-diyl) dicarbamate i.e. ombitasvir, compound (I), which is a potent HCV NS5A inhibitor. In one embodiment, a crystalline form of Compound (I) has characteristic peaks in the PXRD pattern as shown in one of FIGS. 1-11.Type: ApplicationFiled: April 25, 2017Publication date: July 4, 2019Applicant: AbbVie Inc.Inventors: Paul J. Brackemeyer, Colleen C. Garrett, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Geoff G. Zhang, Donghua Zhu
-
Patent number: 9469673Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (° 2?) of 10.7, 11.6, 12.7, 13.0, 13.2, 13.7, 14.5, 18.7, 19.0, and 19.9 after equilibration at 43% relative humidity.Type: GrantFiled: July 11, 2013Date of Patent: October 18, 2016Assignee: AbbVie Inc.Inventors: Ahmad Y. Sheikh, Moiz Diwan, Agnes E. Pal, Yuchuan Gong, Paul J. Brackemeyer, Geoff Zhang, Seble Wagaw
-
Patent number: 9464078Abstract: The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.Type: GrantFiled: September 21, 2011Date of Patent: October 11, 2016Assignee: AbbVie Inc.Inventors: Shuang Chen, James J. Napier, Geoff G. Z. Zhang, Paul J. Brackemeyer
-
Publication number: 20150239882Abstract: The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.Type: ApplicationFiled: May 8, 2015Publication date: August 27, 2015Inventors: Shuang Chen, James J. Napier, Geoff G.Z. Zhang, Paul J. Brackemeyer
-
Patent number: 9108948Abstract: Compounds of formula (I) wherein R1, R2, R3, R3a, R3b, R4, and R5 are defined in the description, are useful in treating conditions or disorders prevented by or ameliorated by histamine-3 receptor ligands. Also disclosed are pharmaceutical compositions comprising the histamine-3 receptor ligands, methods for using such compounds and compositions, and a process for preparing compounds within the scope of formula (I).Type: GrantFiled: December 14, 2007Date of Patent: August 18, 2015Assignee: AbbVie Inc.Inventors: Huaqing Liu, Lawrence A. Black, Youssef L. Bennani, Marlon D. Cowart, Zhenping Tian, Paul J. Brackemeyer
-
Publication number: 20150175612Abstract: The present invention features crystalline forms of Compound I. In one embodiment, a crystalline form of Compound I has characteristic peaks in the PXRD pattern at values of two theta (°2?) of 6.0, 6.7, 10.4, 11.9, 17.5, 17.7, 21.5, 22.0, 22.7, and 24.2.Type: ApplicationFiled: December 3, 2014Publication date: June 25, 2015Applicant: AbbVie Inc.Inventors: Paul J. Brackemeyer, Moiz Diwan, Yuchuan Gong, Agnes E. Pal, Ahmad Y. Sheikh, Seble H. Wagaw, Geoff G. Zhang
-
Publication number: 20150158867Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.Type: ApplicationFiled: February 17, 2015Publication date: June 11, 2015Inventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Marc Scanio, Lei Shi, Chih-Hung Lee, William H. Bunnelle, Geoff G.Z. Zhang, Paul J. Brackemeyer, Shuang Chen, Rodger F. Henry
-
Patent number: 8987453Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.Type: GrantFiled: October 16, 2012Date of Patent: March 24, 2015Assignee: AbbVie Inc.Inventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Marc Scanio, Lei Shi, Chih-Hung Lee, William H. Bunnelle, Geoff G. Z. Zhang, Paul J. Brackemeyer, Shuang Chen, Rodger F. Henry
-
Patent number: 8633317Abstract: Salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.Type: GrantFiled: June 8, 2011Date of Patent: January 21, 2014Assignee: AbbVie Inc.Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
-
Patent number: 8592589Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.Type: GrantFiled: December 17, 2012Date of Patent: November 26, 2013Assignee: AbbVie Inc.Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
-
Patent number: 8513243Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: GrantFiled: July 28, 2011Date of Patent: August 20, 2013Assignee: AbbVie Inc.Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
-
Patent number: 8362014Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: GrantFiled: September 15, 2010Date of Patent: January 29, 2013Assignee: AbbVie Inc.Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
-
Patent number: 8357804Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.Type: GrantFiled: June 9, 2011Date of Patent: January 22, 2013Assignee: AbbVie Inc.Inventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
-
Patent number: 8314119Abstract: The invention relates to compounds that are azaadamantane derivatives, particularly ether- or amine-substituted azaadamantane derivatives and salts and prodrugs thereof, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.Type: GrantFiled: November 5, 2007Date of Patent: November 20, 2012Assignee: AbbVie Inc.Inventors: Michael R. Schrimpf, Diana L. Nersesian, Kevin B. Sippy, Jianguo Ji, Tao Li, Marc Scanio, Lei Shi, Chih-Hung Lee, William H. Bunnelle, Geoff G. Z. Zhang, Paul J. Brackemeyer, Shuang Chen, Rodger F. Henry
-
Publication number: 20120245195Abstract: The invention relates to a crystalline monohydrate of (4s)-4-(5-phenyl-1,3,4-thiadiazol-2-yloxy)-1-azatricyclo[3.3.1.13,7]decane dihydrogen citrate, compositions comprising such compound, and a process for preparing such compound.Type: ApplicationFiled: September 21, 2011Publication date: September 27, 2012Applicant: ABBOTT LABORATORIESInventors: Shuang Chen, James J. Napier, Geoff G.Z. Zhang, Paul J. Brackemeyer
-
Publication number: 20120214848Abstract: The present invention relates to salts and crystalline forms of [1,2,4]oxadiazol-3-yl]-phenoxy}-cycloalkyl carboxylic acids, processes for their preparation, pharmaceutical compositions comprising such compounds, and methods of using them.Type: ApplicationFiled: February 17, 2012Publication date: August 23, 2012Applicant: ABBOTT LABORATORIESInventors: Geoff G. Zhang, Paul J. Brackemeyer, Shaung Chen, Thomas D. Gordon
-
Publication number: 20120203002Abstract: Salts of N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea and crystalline forms thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.Type: ApplicationFiled: June 8, 2011Publication date: August 9, 2012Applicant: ABBOTT LABORATORIESInventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
-
Publication number: 20120149726Abstract: N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea free base and crystallines form thereof are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of disease, for example, cancer.Type: ApplicationFiled: June 9, 2011Publication date: June 14, 2012Applicant: ABBOTT LABORATORIESInventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Ahmad Y. Sheikh
-
Publication number: 20110294811Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: July 28, 2011Publication date: December 1, 2011Applicant: ABBOTT LABORATORIESInventors: Geoff G. Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt
-
Publication number: 20110071151Abstract: ABT-263 free base and crystalline forms thereof are suitable active pharmaceutical ingredients for pharmaceutical compositions useful in treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.Type: ApplicationFiled: September 15, 2010Publication date: March 24, 2011Applicant: ABBOTT LABORATORIESInventors: Geoff G.Z. Zhang, Paul J. Brackemeyer, Nathaniel D. Catron, Thomas B. Borchardt